Melanoma · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Imatinib monotherapy Variant #17 | KIT | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Dacarbazine monotherapy Variant #01 | NRAS | R 2 094 | 21d | 1.5 mo | 9.6 mo | 3 | R 6 282 PFS proxy | 6 |
Binimetinib monotherapy Variant #01 Partial | NRAS | — | 21d | 2.8 mo | — | 5 | — | 1 |
3 of 3 regimens shown